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Abstract
Background: The efficacy of inhaled corticosteroids (ICS) for chronic obstructive pulmonary disease (COPD) varies
between patients, which may be partially due to genetic differences. A single-nucleotide polymorphism, rs37972, in
the glucocorticoid-induced transcript 1 gene (GLCCI1) has been associated with variations in response (forced
expiratory volume in 1 s [FEV1] and residual volume) to fluticasone propionate (Groningen and Leiden Universities
Study of Corticosteroids in Obstructive Lung Disease [GLUCOLD] study). The aim of this study was to determine
whether variation in the GLCCI1 gene at rs37973 is associated with ICS response in patients with COPD.
Methods: Variations in the GLCCI1 gene, rs37973 (which is in almost complete linkage disequilibrium with rs37972) were
examined in 402 corticosteroid-treated, non-Hispanic Caucasian COPD patients, and in 63 GLUCOLD study patients.
Results: We were unable to confirm a genetic association between GLCCI1 and change in FEV1, unlike equivalent data
generated for rs37973 from the GLUCOLD study sample. This was despite accounting for differences in gender, baseline
FEV1, severity of COPD, extent of reversibility, and combination therapy of ICS with bronchodilators.
Conclusions: We conclude that based on changes in FEV1, there is no evidence that the GLCCI1 variant rs37973 has an
impact on corticosteroid response in patients with COPD.
Trial registration: GSK study number HZC112206 (ClinicalTrials.gov identifier: NCT01053988. Registered January 14 2010)
and HZC112207 (ClinicalTrials.gov identifier: NCT01054885. Registered January 14 2010).
Keywords: Chronic obstructive pulmonary disease, Inhaled corticosteroids, Genetic association, GLCCI1, Fluticasone furoate,
Fluticasone propionate
Background
Worldwide, more than 300 million people suffer from
chronic obstructive pulmonary disease (COPD), a pro-
gressive respiratory disease for which there is no cure.
Treatments such as long-acting beta-agonists and long-
acting anticholinergic drugs with and without inhaled cor-
ticosteroids (ICS), may improve quality of life, and reduce
symptoms and the frequency of COPD exacerbations [1].
The response to treatment for COPD may be differen-
tially influenced by the nature of the underlying disease
and the genetic background of the patient. Previous
reports have suggested that the minor allele of the gluco-
corticoid-induced transcript 1 gene (GLCCI1) promoter
variant rs37972 is associated with a poorer ICS treat-
ment response in Caucasians with asthma [2]. GLCCl1
encodes the glucocorticoid-induced transcript 1 gene,
which has been suggested to be an early marker of
glucocorticoid-induced apoptosis [3]. The study by Tan-
tisira et al. [2] also showed that the minor allele of
rs37973, which is in almost complete linkage disequilib-
rium with rs37972 (r2 = 0.97), was associated with
reduced expression of GLCCI1. A further study found
no statistically significant association between the
GLCCI1 single-nucleotide polymorphism (SNP) rs37973
and ICS responsiveness in patients with asthma [4];
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however, the direction of the effect was the same as re-
ported in the study by Tantisira et al. [2]. Vijverberg et
al. also found that the GLCCI1 gene had no effect on
ICS response in children with asthma [5]. In a study of
Japanese patients with asthma, those who were homozy-
gous for the rs37973 minor allele (GG), experienced a
greater decline in lung function over a 4-year period
than patients with other rs37973 genotypes independ-
ently of ICS use [6]. Taken together, these studies
suggest that compared with the major allele, the minor
allele of the GLCCI1 SNP rs37973 could have a poorer
response to ICS treatment in patients with asthma,
though with a small effect size.
Previously, van den Berge et al. [7] reported that
patients with moderate-to-severe COPD who carried the
minor allele (T) of GLCCI1 SNP rs37972 had a poorer
lung function response to ICS treatment than patients
who were homozygous for the major allele (CC) [6]. Al-
though the study only assessed 63 patients, these results
may be important, as they may help to develop strategies
for personalized treatment in patients with COPD.
The present study (GSK study number 200367) evalu-
ated the potential association between GLCCI1 rs37973
and ICS response as a post-hoc analysis using a much
larger sample from two double-blind, randomized trials
of the ICS, fluticasone furoate (FF), in patients with
moderate-to-severe COPD. The aim of this study was to
determine whether variation in the GLCCI1 gene at




Patients were taking part in one of two 6-month double-
blind, randomized, controlled trials, from which the pri-
mary results have been published previously HZC112206
(Study 1: Kerwin et al. [8], ClinicalTrials.gov identifier:
NCT01053988) and HZC112207 (Study 2: Martinez et
al. [9], ClinicalTrials.gov identifier: NCT01054885),
which evaluated the efficacy and safety of FF in patients
with COPD. Study participants included in this analysis
consented to genetic research, provided a DNA sample,
were randomized to receive FF monotherapy only, and
self-reported as non-Hispanic whites. Among the 402
Caucasian patients who satisfied these criteria, 148
(36.8%) were treated with FF inhalation powder 100 μg
once daily (OD) and the remainder with FF 200 μg OD;
for these analyses, treatment effect was assessed at
3 months. All patients were adults of ≥40 years of age.
All patients with COPD participating in the Groningen
and Leiden Universities Study of Corticosteroids in
Obstructive Lung Disease (GLUCOLD) study [10] were
also included in this analysis. In this double-blind study,
patients were randomly assigned to receive one of four
treatments: 1) fluticasone propionate (FP) 500 μg twice
daily (BID) for 30 months; 2) FP/salmeterol 500/50 μg
BID for 30 months; 3) placebo BID for 30 months; or 4)
FP 500 μg BID for the first 6 months followed by pla-
cebo BID for 24 months.
All studies were performed in accordance with the
Declaration of Helsinki and approved by local medical
ethics committees and all patients gave their written in-
formed consent to participate.
Genetic markers
Genotyping for the rs37972 and rs37973 SNPs was per-
formed for Studies 1 and 2, and the GLUCOLD study by
competitive allele-specific polymerase chain reaction ampli-
fication of target sequences and endpoint fluorescence geno-
typing (KASPar™) KBiosciences (Hoddesdon, UK). Here, we
report on rs37973 only, as this variant is known to alter
GLCCI1 gene expression and is in almost complete linkage
disequilibrium (r2 = 0.97) with rs37972 [2].
Primary endpoints
For these analyses, the primary endpoint was the
strength of association between the rs37973 SNP and
change in the forced expiratory volume in 1 s (FEV1) at
Week 12, reported as percent of predicted FEV1
(FEV1%pred), adjusting for variables nominally associ-
ated with change of FEV1%pred at Week 12. The GLU-
COLD study had the same primary endpoint.
Clinical response was defined as change in trough
(pre-bronchodilator) FEV1%pred from baseline to Day
84 (Week 12) of treatment with FF. For Studies 1 and 2,
trough FEV1 was calculated by taking the mean of the
two FEV1 measurements at 23 and 24 h following the
Day 83 dose. In the GLUCOLD study, we measured
change in post-bronchodilator FEV1 also after 12 weeks.
Statistical methods
In Studies 1 and 2, a sample size of 402 gave statistical
power of approximately 100% to demonstrate an additive
association between rs37973 and change in FEV1%pred
with ICS treatment. This calculation assumed a 1-sided
test, a minor allele frequency of 40%, an alpha error of
0.05, a mean change between the homozygotes of 5.4%,
and genotype-specific standard errors of ±4.9% and ±6.9%
for CC and TT, respectively, as previously published [7].
Preliminary analyses indicated that there were statisti-
cally significant differences in patient characteristics (base-
line FEV1 –200 ml) between those participating in Study 1
and those participating in Study 2. Therefore, associations
between genotype and changes in FEV1%pred with ICS
treatment were assessed separately within each study and
the results combined using an inverse variance-weighted
meta-analysis that assumed fixed effects.
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For Study 1, the distribution of the change in FEV1%pred
was approximately normal and no data transformation was
necessary. For Study 2, the Shapiro-Wilk statistic was highly
significant; therefore, an inverse normal transformation was
applied.
Covariate selection was conducted separately for Studies
1, 2, and the GLUCOLD study. The covariates investi-
gated included age, gender, height, weight, body mass
index (BMI), country, study center group, smoking status
(current or former), pack-years smoking, FEV1 at baseline,
FEV1%pred at baseline, forced vital capacity (FVC), and
FEV1/FVC at baseline. After identifying variables that had
univariate significant associations with the response vari-
able, a forward-reverse stepwise analysis was performed in
which the criterion for entry into the model was p = 0.25
and the criterion for staying in the model was p = 0.05.
After following this procedure, only pack-years smok-
ing was retained for Study 1, and only FEV1%pred at
baseline was retained for Study 2. In the GLUCOLD
study, BMI and smoking status were retained in the
final model.
Linear regression with an additive model was used to
assess the effect of rs37973 on change from baseline in
trough FEV1%pred from baseline. This was performed
separately for Studies 1 and 2. The statistical model in-
cluded the rs37973 genotype, coded as 0, 1, or 2 based
on the number of minor alleles present, and the covari-
ates identified by the covariate selection process within
each study.
Results
The clinical characteristics of patients included in Study
1, 2, and the GLUCOLD study are presented in Table 1.
The main difference between the studies (Table 1;
Additional file 1: Tables S1 and S2) was that patients in
Studies 1 and 2 had more severe COPD at baseline than
patients in the GLUCOLD study.
In Studies 1 and 2, the frequency of the rs37973 minor
allele (G) was 42.5%, comparable with earlier publica-
tions [2, 4, 6]. There was no evidence for deviation from
Hardy-Weinberg equilibrium (p = 0.54).
The frequencies for rs37973 genotypes AA, AG, and
GG in Study 1 (n = 94) were 28%, 54%, and 18%, respect-
ively, and in Study 2 (n = 308) were 36%, 45%, and 19%,
respectively. For the GLUCOLD study (n = 63), the fre-
quencies were 33%, 50%, and 17%, respectively.
In Study 1 (n = 94), there was no evidence for an associ-
ation between the minor allele and poorer response based
on change in trough FEV1%pred (1-sided p = 0.17).
Analysis of unadjusted change in FEV1%pred by rs37973
genotype (Fig. 1a) indicates that the genotype with the nu-
merically poorest response was AG (p = 0.036 for AA ver-
sus AG; p = 0.16 for GG versus AG). This is in contrast to
previous findings where patients with the TT genotype
(rs37972) had the poorest response [6].
In Study 2 (n = 308), there was no association between
rs37973 genotypes and change in trough FEV1%pred
(unadjusted values, Fig. 1b; 1-sided p = 0.98). A sensitiv-
ity analysis exploring the effect of transformation and
covariate adjustment on change in FEV1 by rs37973
genotype was performed in Study 2 using four different
scenarios; in general, the results were similar in each
scenario (Additional file 1: Appendix 1; Table S3).
In the GLUCOLD study (n = 63), the heterozygote
(AG) and minor allele homozygote (GG) genotypes were
associated with less improvement in FEV1%pred com-
pared with the major allele homozygotes (AA; p = 0.045
and p = 0.048, respectively; Fig. 1c).
Meta-analysis of study 1 and 2
The combined estimate for the additive effect of the
rs37973 minor allele on change in trough FEV1%pred
(adjusted for covariates) was significantly different from
0 at 0.16% (2-sided p = 0.037; 95% confidence interval:
0.01–0.31). However, in contrast with previous observa-
tions [7], the parameter estimate was positive, indicating
that the minor allele (G) of rs37973 was associated with
a better FEV1 %pred response (Fig. 1b) versus the major
allele rather than the expected poorer response. A 1-
sided test of the null hypothesis that the minor allele is
associated with a better response to FF treatment was
not rejected at p = 0.98.
Table 1 Comparison of baseline characteristics and change in trough FEV1 at week 12 in studies 1 and 2, and in the GLUCOLD study
Variables Study 1 (n = 94) Study 2 (n = 308) p value GLUCOLD (n = 63)
Age, years 61.3 (0.9) 61.2 (0.5) 0.937 62.1 (1.02)
BMI, kg/m2 27.5 (0.6) 27.1 (0.3) 0.482 25.5 (0.48)
FEV1 at baseline, L 1.2 (0.04) 1.4 (0.03) 0.008 2.0 (0.05)
FEV1%pred at baseline 42.1 (1.1) 44.5 (0.8) 0.113 63.1 (1.1)
FEV1/FVC at baseline, % 48.3 (1.2) 46.1 (0.7) 0.111 50.8 (1.1)
Change in trough FEV1 as a % of predicted at Week 12 2.5 (0.8) 0.5 (0.4) 0.013 0.5 (0.8)
p values shown are for differences between Studies 1 and 2
Values are mean (standard error) unless otherwise stated
BMI, body mass index, FEV1, forced expiratory volume in 1 s, FEV1%pred percent of predicted forced expiratory volume in 1 s, FVC forced vital capacity, GLUCOLD
Groningen and Leiden Universities Study of Corticosteroids in Obstructive Lung Disease
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Discussion
COPD is a heterogeneous disease that shows some
inter-individual variability in response to several drugs.
Compared with COPD patients carrying the major allele
(C) of the GLCCI1 SNP rs37972, patients carrying the
minor allele (T) have been previously shown to have a
poorer 3-month and 6-month FEV1 response to ICS
treatment [7]. To assess the strength of this association,
we analyzed data from two double-blind, randomized,
controlled studies of non-Hispanic Caucasian patients
treated with FF. We found no significant association be-
tween the minor allele of the functional GLCCI1 SNP
rs37973 (G) and poorer ICS treatment response in either
of the two independent COPD cohorts studied. In con-
trast to previous studies, a meta-analysis of the two in-




Fig. 1 a Unadjusted change in FEV1%pred in Study 1 by rs37973 genotype; b unadjusted change in FEV1%pred in Study 2 by rs37973 genotype;
c unadjusted change in FEV1%pred in the GLUCOLD study by rs37973 genotype FEV1%pred, percent of predicted forced expiratory volume in 1 s;
GLUCOLD, Groningen and Leiden Universities Study of Corticosteroids in Obstructive Lung Disease
Mosteller et al. COPD Research and Practice  (2017) 3:2 Page 4 of 6
the rs37973 minor allele (G) was associated with a statis-
tically significant improvement in FEV1%pred after
3 months of FF treatment.
The results from the GLUCOLD study presented in
this paper are very similar, but not identical to, the ori-
ginal publication [7]. In the current study, we genotyped
samples for the functional SNP, rs37973, that is highly
correlated with rs37972. To compare directly with the
results of the two independent COPD cohorts (Studies 1
and 2) we performed a linear regression under an addi-
tive model with covariates. In contrast, data in the ori-
ginal publication [7] were analysed using an unpaired t
test. These features may explain the slight discrepancy in
p-values between the two studies.
We considered several possible factors that might ex-
plain the contradictory findings in the GLUCOLD study
compared with the two independent COPD cohorts.
Firstly, it is important to mention that in the GLUCOLD
study, patients with COPD who received FP monother-
apy or combined FP and salmeterol were analyzed to-
gether, whereas the analyses of Studies 1 and 2 were
performed in COPD patients treated with FF alone. For
this reason, we re-analyzed our data from the GLU-
COLD study patients treated with FP alone, and simi-
larly found that the minor allele (G) still predicted
smaller changes in FEV1 after 3 months of treatment,
thus not explaining differences in results.
Secondly, the GLUCOLD study predominantly included
males, whereas the Study 1 and 2 cohorts included both
males and females. However, a gender-specific separate
analysis of males and females gave results that were com-
parable to the total GLUCOLD study sample.
We also investigated subsets of Studies 1 and 2 to align
our analysis with the features of the GLUCOLD study [7].
Previous ICS use, including run-in time, did not explain
the differences in ICS response by genotype between
Studies 1 and 2 and the GLUCOLD studies. Differences
between studies in baseline FEV1, severity of disease, and
the extent of reversibility did not explain the differences
observed in response by genotype. Further, the GLU-
COLD study differed in dosage and duration of treatments
compared with Studies 1 and 2. However, we found no
dosage effect and we were only able to compare treatment
outcome after 3 months for the three studies.
Finally, the GLUCOLD study examined additional pul-
monary function parameters, such as residual volume
(RV). We were unable to replicate these results as the
information on RV was unavailable in Studies 1 and 2,
and unfortunately, it has no clear surrogate.
Conclusions
We conclude that the minor allele of the GLCCI1 SNP
rs37973 (G) is not associated with poorer ICS respon-
siveness in COPD, as measured by change in trough
FEV1%pred. In contrast, in some patients, it may even
predict a better outcome with ICS treatment. We thus
did not replicate earlier findings in the GLUCOLD
study. Significant disease heterogeneity makes it difficult
to compare data from the three studies. However, we
have excluded the major factors that led to this hetero-
geneity as reasons for our inability to confirm the find-
ings from the original study.
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